Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-978 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT05879744Phase 1Terminated
- Sponsor
- Cullinan Therapeutics
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CLN-978 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Cullinan Therapeutics. Primary endpoints: Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs at 24 months and Define dose regimen for CLN-978 at 24 months. Started May 2023; status: terminated.
02
Drugs
CLN-978
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05879744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879744.